Andrea S. James bought $200k of IMDX
Chief Financial Officer at Insight Molecular Diagnostics Inc.. 97,561 shares at an average of $2.05, traded Feb 7, 2025, filed Feb 11, 2025.
Score components
- +22RoleCFO
- +12Trade size$200k at market
- +10Relative to holdingsHoldings up 182%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-25-005978, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 7, 2025 | POpen-market purchase Common Stock, no par value | +97,561 | $2.05 | $200k | 151,231 | Feb 11, 2025 |
Related signals
Other insiders at Insight Molecular Diagnostics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Insight Molecular Diagnostics Inc. | Broadwood Partners, L.p. owner | $11M 5,165,695 shares | +83% | |
| 30Weak | Insight Molecular Diagnostics Inc. | Patrick W Smith owner | $192k 90,219 shares | +5% | |
| 31Weak | Insight Molecular Diagnostics Inc. | Andrew Arno director | $26k 12,500 shares | +18% | |
| 38Weak | IMDXbuy Insight Molecular Diagnostics Inc. | Andrea S. James Chief Financial Officer | $46k 20,000 shares | +59% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.